Specialized Working Group on Acute Myeloid Leukemia

Overview

The AML Specialized Working Group (SWG) operates under the umbrella of EHA and brings together internationally recognized clinical and research experts dedicated to advancing the understanding of AML biology and improving patient care.

The key objectives of the SWG are:

• To provide a collaborative platform for translational research bridging basic science and clinical practice
• To improve patient outcomes
• To enhance patient and public awareness of AML
• To educate and mentor clinicians and scientists, with a strong focus on supporting early-career professionals.

The SWG actively promotes the integration and development of young AML researchers and clinicians by offering networking opportunities and early involvement in research and clinical initiatives, thereby fostering the next generation of European leaders in the field. In addition, the group engages in constructive collaboration with industry partners.

Throughout 2025, the AML SWG has remained closely aligned with EHA’s core ambitions, contributing to:

• Research initiatives
• Educational efforts (such as the EHA Annual Congress, Tutorials, specialized meetings, and EHA educational programs)
• Broader European outreach, including engagement with institutions and health technology assessment bodies

The group’s activities encompass the design and support of clinical trials, research on supportive care, observational studies on rare events, epidemiological analyses, and quality-of-life research. The SWG also contributes to the development of clinical guidelines and recommendations and supports a wide range of research initiatives focused on AML biology. A key priority is the promotion of harmonized real-world data collection and integration to advance precision medicine and generate robust evidence for both regulatory and scientific purposes.

As part of a well-established international AML network, the AML SWG actively initiates and collaborates with global AML cooperative groups, strengthening international partnerships and scientific exchange.

In summary, the AML SWG remains an integral component of EHA, driven by a shared commitment to improving outcomes for patients with AML and to sustaining a dynamic and collaborative ecosystem of research, education, and innovation.

Join us

If you work in our field and share our mission to advance our understanding of AML, you’d be welcome to join our SWG. However, before you apply, we recommend you read our application guidance.

Ready? Apply now on the EHA Portal.

If you have any questions, please email our SWGs team.